Thermo Fisher Scientific (TMO) Cost of Revenue (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Cost of Revenue for 18 consecutive years, with $3.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 12.69% year-over-year to $3.6 billion; the trailing twelve-month figure through Jun 2026 stood at $14.0 billion (up 9.65% YoY), and the FY2025 full-year result was $13.4 billion, up 5.93% from the prior year.
• Cost of Revenue grew to $3.6 billion in Q2 2026 per TMO's latest filing, from $3.3 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $3.7 billion in Q4 2025 and bottomed at $3.1 billion in Q2 2024.
• Historically, Cost of Revenue has averaged $3.4 billion across 5 years, with a median of $3.3 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 10487.88% in 2022, then dropped 9.32% in 2023.
• Over 5 years, Cost of Revenue stood at $3.7 billion in 2022, then dropped by 9.32% to $3.3 billion in 2023, then dropped by 2.99% to $3.2 billion in 2024, then grew by 14.91% to $3.7 billion in 2025, then retreated by 1.93% to $3.6 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.6 billion, $3.3 billion, and $3.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.